8-K: Finch Therapeutics Faces Delisting from Nasdaq Global Select Market Due to Non-Compliance

Finch Therapeutics has received an additional delisting notice from Nasdaq due to its failure to maintain the required market value of publicly held shares, and is requesting a transfer to the Nasdaq Capital Market.

Summary

• Finch Therapeutics received a deficiency letter from Nasdaq on November 15, 2023, for not meeting the minimum market value of publicly held shares requirement of $5.0 million.
• The company was given until May 13, 2024, to regain compliance, but failed to do so.
• On May 14, 2024, Nasdaq issued an additional determination for delisting due to continued non-compliance.
• Finch Therapeutics had previously appealed a determination that it is a public shell, with a hearing on April 23, 2024.
• The Nasdaq Listing Panel will consider both the public shell status and the market value non-compliance in its decision.
• On May 15, 2024, Finch requested a transfer of its listing to the Nasdaq Capital Market.
• There is no guarantee that the appeal will be successful or that the transfer will be granted.
• Even if the transfer is granted, there is no assurance that the company will maintain compliance with all listing criteria.

Sentiment

Score: 3

Explanation: The document indicates significant negative developments with the company facing delisting and uncertainty about its future listing status. The sentiment is negative due to the failure to meet listing requirements and the risk of delisting.

Positives

• Finch Therapeutics has requested a transfer to the Nasdaq Capital Market, which could allow it to remain listed.

Negatives

• Finch Therapeutics failed to meet the Nasdaq minimum market value of publicly held shares requirement.
• The company received an additional delisting determination from Nasdaq.
• There is no guarantee that the appeal or the transfer request will be successful.
• The company is also under review for being a public shell.

Risks

• The company faces the risk of being delisted from the Nasdaq Global Select Market.
• There is no assurance that the company will be able to maintain compliance with listing criteria even if the transfer to the Nasdaq Capital Market is granted.
• The Nasdaq Listing Panel could uphold the delisting determination.
• The company's public shell status is also under review.

Future Outlook

The company's future listing status is uncertain, pending the Nasdaq Listing Panel's decision on the delisting appeal and the request for transfer to the Nasdaq Capital Market. There is no guarantee of continued listing on any exchange.

Management Comments

• The company has submitted a request to the Listing Panel for the transfer of the listing of the Common Stock to The Nasdaq Capital Market.

Industry Context

This situation highlights the challenges faced by smaller biotech companies in maintaining listing compliance, particularly in volatile market conditions. Many companies in the sector are facing similar pressures to maintain market capitalization and avoid delisting.

Comparison to Industry Standards

• Many small-cap biotech companies struggle to maintain the minimum market capitalization required by major exchanges like Nasdaq.
• Companies like Finch, which are in the development stage, often face challenges in maintaining share value due to the inherent risks and long timelines associated with drug development.
• Other companies that have faced similar delisting notices include those with limited revenue and high cash burn rates, which are common in the biotech sector.
• The request to transfer to the Nasdaq Capital Market is a common strategy for companies facing delisting from the Global Select Market, as the Capital Market has less stringent requirements.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may experience uncertainty about the company's future.
• The company's ability to raise capital may be negatively impacted.

Next Steps

• The Nasdaq Listing Panel will review the company's appeal of the delisting determination.
• The Nasdaq Listing Panel will review the company's request for transfer to the Nasdaq Capital Market.
• The company will need to maintain compliance with all applicable listing criteria if the transfer is granted.

Key Dates

Keywords

delisting, Nasdaq, market value, public shell, compliance, listing, Finch Therapeutics, transfer, MVPHS Rule